Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | PNP | P00491 | 3/20 | 0.46 |
| ▸ | TK1 | P04183 | 2/20 | 0.45 |
| ▸ | BLM | P54132 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | EDNRA | P25101 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | HBB | P68871 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.43 |
| ▸ | VCP | P55072 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3514475 | 0.87 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL28384881 | 0.86 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL3970963 | 0.86 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL13756819 | 0.86 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL28899787 | 0.86 | ADORA3 (0.48) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL13626438 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL18537401 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL116166 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL29479236 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 | |
| SCHEMBL3018983 | 0.85 | ADORA3 (0.47) | ADORA3PNPTK1BLMUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | claimed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | claimed |
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | MIRECA MEDICINES GMBH (DE) | 2025-08-12 | — | — | US | disclosed |
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | MIRECA MEDICINES GMBH (DE) | 2024-10-24 | — | — | US | disclosed |
| EP-4399215-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | Mireca Medicines GmbH (DE) | 2024-07-17 | — | — | EP | disclosed |
| CN-117999269-A | Improved process for producing cyclic guanosine monophosphate analogues | 米雷卡医药有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | MIRECA MEDICINES GMBH (DE) | 2023-08-03 | — | — | US | disclosed |
| WO-2023031481-A1 | IMPROVED METHODS FOR PRODUCTION OF CYCLIC GUANOSINE-MONOPHOSPHATE ANALOGUES | MIRECA MEDICINES GMBH (DE) | 2023-03-09 | — | — | WO | disclosed |
| EP-3353298-A2 | ALLELE SELECTIVE GENE EDITING AND USES THEREOF | Arcturus Therapeutics, Inc. (US) | 2018-08-01 | — | — | EP | disclosed |
| EP-3277811-A1 | FULLY STABILIZED ASYMMETRIC SIRNA | University of Massachusetts (US) | 2018-02-07 | — | — | EP | disclosed |
| WO-2017053431-A2 | ALLELE SELECTIVE GENE EDITING AND USES THEREOF | ARCTURUS THERAPEUTICS, INC. (US) | 2017-03-30 | — | — | WO | disclosed |
| CN-101796191-B | For transfection and the mixture for immunostimulating RNA and cationic peptide | CUREVAC GMBH (DE) | 2015-11-25 | — | — | CN | disclosed |
| CN-104968354-A | Methods of increasing the viability or longevity of an organ or organ explant | modeRNA Therapeutics | 2015-10-07 | — | — | CN | disclosed |
| CN-104870022-A | In vivo production of proteins | modeRNA Therapeutics | 2015-08-26 | — | — | CN | disclosed |
| CN-104840953-A | Compositions for treating prostate cancer (PCa) | CUREVAC GMBH | 2015-08-19 | — | — | CN | disclosed |
| CN-104411338-A | Modified polynucleotides for production of biologics and proteins associated with human diseases | modeRNA Therapeutics | 2015-03-11 | — | — | CN | disclosed |
| CN-104114572-A | Modified nucleosides, nucleotides and nucleic acid compositions | MODERNA THERAPEUTICS INC | 2014-10-22 | — | — | CN | disclosed |
| CN-101820899-B | Composition for treating lung cancer, particularly of non-small lung cancers (NSCLC) | CUREVAC GMBH | 2014-03-12 | — | — | CN | disclosed |
| US-20020177695-A1 | Nucleic acid probes and methods | DUKE UNIVERSITY | 2002-11-28 | — | — | US | disclosed |
| US-6288221-B1 | REPLACING NUCLEOSIDE WITH DIMETHOXYTRITYL, PHOSPHORAMIDITE, OR HALONUCLEOSIDE DERIVATIVE; ELECTROCHEMICAL OR PHOTOCHEMICAL DETECTION OF NUCLEIC ACID SEQUENCES | DUKE UNIVERSITY | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242568-A1 | POLYMER LINKED MULTIMERS OF GUANOSINE-3', 5'-CYCLIC MONOPHOSPHATES | PRKG1, PRKG2, PRKAG3 | ADORA3 425/4885PNP 111/4885TK1 460/4885 |
| US-12384813-B2 | Polymer linked multimers of guanosine-3′, 5′-cyclic monophosphates | PRKG1, PRKG2, PRKAG3 | ADORA3 435/4885PNP 107/4885TK1 451/4885 |
| US-20240352056-A1 | Improved methods for production of cyclic guanosine-monophosphate analogues | GMPS, CGAS, AMPD3 | ADORA3 708/4885PNP 15/4885TK1 187/4885 |
| US-20020177695-A1 | Nucleic acid probes and methods | NUDT1, NT5C3B, NT5C2 | ADORA3 80/4885PNP 6/4885TK1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.